Evidence map›Paper›PMID 31888713›Full record

Trial reportTrials2019

Efficacy of Bimin decoction for patients with perennial allergic rhinitis: an open-label non-inferiority randomized controlled trial.

Jingyi Zhao, Xinyu Yan, Jianqing Gai, Jinshuai Han, Hong Zhang, Hui Luo, Shaoting Huang, Junge Wang

Open access · goldAbstract readEquivalence TrialRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Trials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Efficacy and safety ofAnnals of translational medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jingyi ZhaoDepartment of Otolaryngology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23 Back Street of Art Museum, Beijing, 100010, People's Republic of China.
Xinyu YanDepartment of Otolaryngology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23 Back Street of Art Museum, Beijing, 100010, People's Republic of China.
Jianqing GaiDepartment of Otolaryngology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23 Back Street of Art Museum, Beijing, 100010, People's Republic of China.
Jinshuai HanDepartment of Otolaryngology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23 Back Street of Art Museum, Beijing, 100010, People's Republic of China.
Hong ZhangDepartment of Otolaryngology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23 Back Street of Art Museum, Beijing, 100010, People's Republic of China.
Hui LuoDepartment of Otolaryngology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23 Back Street of Art Museum, Beijing, 100010, People's Republic of China.
Shaoting HuangDepartment of Otolaryngology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23 Back Street of Art Museum, Beijing, 100010, People's Republic of China.
Junge WangDepartment of Otolaryngology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23 Back Street of Art Museum, Beijing, 100010, People's Republic of China. wjgent@163.com.
Beijing Hospital of Traditional Chinese Medicine · CNCapital Medical University · CN

Funding

National Natural Science Foundation of China 81674034Natural Science Foundation of Beijing Municipality 7162081
6 · The paper itself

Abstract

backgroundAllergic rhinitis (AR) is a common allergic disease. It affects people worldwide and traditional Chinese medicine is becoming popular among AR patients because it has a definite clinical effect and there are few adverse reactions. Lung qi deficiency and cold syndrome (LQDCS) is a frequent type of AR, and the Chinese herbal medicine bimin decoction (BMD) is prescribed for it. This study compared the clinical efficacy of BMD for AR patients with LQDCS to the conventional medicine loratadine and fluticasone nasal spray.

methodsThe study was an open-label non-inferiority randomized controlled trial. A total of 108 AR patients with LQDCS aged 19 to 60 were randomly allocated in a 1:1 ratio to the BMD group or the control group by the central computer system in Beijing Hospital of Traditional Chinese Medicine from January 2017 to April 2018. In total, 98 participants completed the study (BMD group n = 51 and control group n = 47). Patients in the BMD group received BMD while those in the control group received fluticasone nasal spray and loratadine tablets for 4 weeks. The primary outcome was the change in the Total Nasal Symptom Score (TNSS) between the baseline and the end of treatment. Changes in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), nasal resistance, and acoustic rhinometry parameters were secondary outcomes. All side effects due to the treatments were recorded.

resultsAfter the 4-week treatment, the total TNSS was significantly reduced in both groups compared to the baseline (P <  0.05). No significant between-groups differences were observed for changes in TNSS scores [- 0.298 (95% confidence interval -0.640 to 0.140)], which was within the defined non-inferiority margin. RQLQ in both groups decreased significantly (P <  0.001) from baseline, though a more obvious reduction was observed for the BMD group (P <  0.001). There were no significant differences in nasal resistance, nasal volume, or nasal minimum cross-sectional area between groups after treatment (P > 0.05).

conclusionsThese findings indicate that BMD helps relieve the symptoms of perennial AR and improves rhinitis-related quality of life. Our study indicates that BMD is non-inferior to loratadine tablets and fluticasone nasal spray for AR patients with LQDCS.

trial registrationChinese Clinical Trial Registry, ChiCTR-INR-16010063. Registered on 2 December 2016.

Indexed as

AdultAnti-Allergic AgentsDrugs, Chinese HerbalFemaleFluticasoneHumansLoratadineMaleMiddle AgedNasal ObstructionNasal SpraysQuality of LifeRhinitis, Allergic, PerennialSneezingSurveys and QuestionnairesTreatment OutcomeAnti-Allergic AgentsbiminneDrugs, Chinese HerbalFluticasoneLoratadineNasal SpraysClinical efficacyPerennial allergic rhinitisRandomized controlled trialTraditional Chinese medicine

Identifiers

PMID31888713
PMCPMC6937845
OpenAlexW2997062871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.